Publications and Presentations
MyNCBI BIBLIOGRAPHY: https://www.ncbi.nlm.nih.gov/myncbi/andrea.bonetto.1/bibliography/public/
PUBLICATIONS (OVER THE PAST 5 YEARS):
1. Bonetto A, Kays JK, Parker VA, Matthews RR, Barreto R, Puppa MJ, Kang KS, Carson JA, Guise TA, Mohammad KS, Robling AG, Couch ME, Koniaris LG, Zimmers TA. Differential bone loss in mouse models of colon cancer cachexia. Front Physiol 7:679 (2017)
2. Mota R, Rodríguez JE, Bonetto A, O’Connell T, Parry TL, Lockyer P, McCudden CR, Asher S, Couch M, Willis MS. Post-Translationally Modified Muscle-Specific Ubiquitin Ligases as Circulating Biomarkers in Experimental Cancer Cachexia. Am J Cancer Res 7(9):1948-1958 (2017)
3. Barreto R, Kitase Y, Matsumoto T, Pin F, Colston KC, Couch KE, O’Connell TM, Couch ME, Bonewald FE, Bonetto A. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep 7(1):14470 (2017)
4. Pin F, Barreto R, Kitase K, Mitra S, Erne CE, Novinger LJ, Zimmers TA, Couch ME, Bonewald LF, Bonetto A. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle, 9(4):685-700 (2018)
5. Pin F, Barreto R, Couch ME, Bonetto A*, O’Connell TM*. Cachexia induced by cancer and chemotherapy yield distinct metabolic perturbations. *co-corresponding authors. J Cachexia Sarcopenia Muscle, 10(1):140-154 (2019)
6. Pin F, Novinger LJ, Huot JR, Harris RA, Couch ME, O’Connell TM, Bonetto A. PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J, 33(6):7778-7790 (2019)
7. Huot JR, Essex AL, Gutierrez M, Barreto R, Wang M, Waning DL, Plotkin LI, Bonetto A. Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 11(4):571 (2019)
8. Pin F, Bonetto A, Bonewald LF, Gordon KL. Molecular Mechanisms Responsible for the Rescue Effects of Pamidronate on Muscle Cachexia in Pediatric Burn Patients. Frontiers in Endocrinology (Lausanne), 10:543 (2019)
9. O’Connell TM, Pin F, Couch ME, Bonetto A. Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia. Cancers (Basel), 11(9):1222 (2019)
10. Mitra S, Tiwari K, Pandhiri T, Podicheti R, Pandhiri T, Rusch DB, Bonetto A, Zhang C, Mitra AK. Transcriptome profiling reveals matrisome alteration is a key feature of ovarian cancer progression. Cancers (Basel), 11(10):1513 (2019)
11. Essex LA, Pin F, Huot JR, Bonewald LF, Plotkin LI, Bonetto A. Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Frontiers in Endocrinology (Lausanne), 10:809 (2019)
12. Huot JR, Novinger LJ, Pin F, Bonetto A. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia. Disease Models and Mechanisms, 13(1):dmm043166 (2020)
13. Alwani M, Jones AJ, Novinger LJ, Pittelkow E, Bonetto A, Sim MW, Moore MJ, Mantravadi AV. The impact of sarcopenia on postoperative outcomes of autologous free tissue transfer in head and neck reconstruction. Journal of Reconstructive Microsurgery, 36(5):369-378 (2020)
14. Huot JR, Novinger LJ, Pin F, Narasimhan A, Zimmers TA, O’Connell TM, Bonetto A. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia. JCI Insight, 5(9):e136687 (2020)
15. Huot JR, Pin F, Narasimhan A, Novinger LJ, Keith AS, Zimmers TA, Willis MS, Bonetto A. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia. J Cachexia Sarcopenia Muscle, 11(6):1779-1798 (2020)
16. Jones AJ, Campiti VJ, Alwani MA, Novinger LJ, Bonetto A, Sim MW, Yesensky JA, Moore MG, Mantravadi AV. Skeletal muscle index's impact on discharge disposition after head and neck cancer free flap reconstruction. Otolaryngology-Head and Neck Surgery, 8:194599820973232 (2020)
17. Kim H-G, Huot JR, Pin F, Guo B, Bonetto A, Nader GA. Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia. FASEB J, 35(2):e21335 (2021)
18. Rupert JE, Narasimhan A, Jengelley DHA, Jiang Y, Liu J, Au E, Silverman L, Bonetto A, Cao S, Lu X, O’Connell TM, Liu Y, KOniaris LG, Zimmers TA. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. Journal of Experimental Medicine, 6(2):200-210 (2021)
19. Jones AJ, Campiti VJ, Alwani MA, Novinger LJ, Bonetto A, Sim MW, Yesensky JA, Moore MG, Mantravadi AV. Sarcopenia is Associated with Blood Transfusions in Head and Neck Cancer Free Flap Surgery. Laryngoscope nvestigative Otolaryngology, 6(2):200-210 (2021)
20. Huot JR, Pin F, Essex AL, Bonetto A. MC38 tumors induce musculoskeletal defects in colorectal cancer. International Journal of Molecular Sciences, 22(3):1486 (2021)
21. Ballarò R, Lopalco P, Audrito V, Beltrà M, Pin F, Angelini R, Costelli P, Corcelli A, Bonetto A, Szeto HH, O’Connell TM, Penna F. Targeting mitochondria by SS-31 ameliorates the whole body energy status in cancer- and chemotherapy-induced cachexia. Cancers (Basel), 13(4):850 (2021)
22. Huot JR, Pin F, Bonetto A. Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity. American Journal of Cancer Research, 11(6):2990-3001 (2021)
23. Pin F, Prideaux M, Huot JR, Essex AL, Plotkin LI, Bonetto A, Bonewald LF. Non-bone metastatic cancers promote osteocyte-induced bone destruction. Cancer Letters, 520:80-90 (2021)
24. O’Connell TM, Golzarri-Arroyo L, Pin F, Barreto R, Stephanie D, Couch M, Bonetto A. Metabolic
biomarkers for the early detection of cancer cachexia. Frontiers in Cell and Developmental Biology, 9:720096 (2021)
25. Pin F, Jones AJ, Huot JR, Narasimhan A, Zimmers TA, Bonewald, LF, Bonetto A. RANKL blockade reduces cachexia and bone loss induced by non-metastatic ovarian cancer in mice. Journal of Bone and Mineral Research, in press (2022)
26. Pin F, Huot JR, Bonetto A. The mitochondria-targeting agent MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice. Frontiers in Cell and Developmental Biology, in press (2022)
27. Jones AJ, Davis KP, Novinger LJ, Bonetto A, Mantravadi AV, Sim MW, Yesensky JA, Moore MG,. Postoperative consequences of cancer cachexia after head and neck free flap reconstruction. Head & Neck, in press (2022)
28. Essex AL, Huot JR, Deosthale P, Wagner A, Figueras J, Davis A, Damrath J, Pin F, Wallace J, Bonetto A, Plotkin LI. TREM2 R47H variant causes distinct age- and sex-dependent musculoskeletal alterations in mice. Journal of Bone and Mineral Research, in press (2022)
29. Huot JR, Pin F, Chatterjee R, Bonetto A. PGC1 overexpression preserves muscle mass and function in cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle, in press (2022)
PRESENTATIONS (OVER THE PAST 5 YEARS):
LOCAL:
Understanding the mechanisms associated with chemotherapy-derived cachexia and muscle weakness
Indiana University Simon Comprehensive Cancer Center
Indianapolis, IN
01/2017
Ovarian cancer causes loss of muscle and bone mass: a new model for the study of cancer cachexia
Indiana University
Indianapolis, IN
06/2018
Mechanisms of cancer- and chemotherapy-induced cachexia
Indiana University Simon Comprehensive Cancer Center
Indianapolis, IN
02/2019
Musculoskeletal deficits induced by cancer and its treatments
Indiana University Simon Comprehensive Cancer Center Seminar Series
Indianapolis, IN
06/2020
Tumor- and host-derived mediators trigger muscle and bone loss in experimental cancer cachexia
Indiana University Simon Comprehensive Cancer Center
Indianapolis, IN
08/2020
Update on Muscle and Bone Crosstalk Research Team
Indiana Center for Musculoskeletal Health
Indianapolis, IN
08/2020
Functional and molecular analysis of muscle in patients with and without head and neck cancer cachexia Indiana Center for Musculoskeletal Health
Indianapolis, IN
08/2020
Consequences of TREM2 mutations in bone and muscle
Indiana Center for Musculoskeletal Health
Indianapolis, IN
08/2020
INTERNATIONAL:
Modeling cachexia: the impact of anti-neoplastic therapy
10th Cachexia Conference
Rome, Italy
12/2017
Understanding the mechanisms associated with chemotherapy-derived cachexia and muscle weakness
University of Torino
Torino, Italy
12/2017
Understanding the mechanisms responsible for cancer- and chemotherapy-derived cachexia
University of Tennessee Health Science Center
Memphis, TN
05/2018
Understanding the mechanisms associated with chemotherapy-derived cachexia and muscle weakness
Loyola University Stritch School of Medicine
Chicago, IL
09/2018
PDK4 drives metabolic alterations and skeletal muscle atrophy in cancer cachexia
4th Cancer Cachexia Conference
Philadelphia, PA
09/2018
PDK4 drives metabolic alterations and skeletal muscle atrophy in cancer cachexia
11th Cachexia Conference
Maastricht, Netherlands
12/2018
Metabolic abnormalities in cancer cachexia
University of Torino
Torino, Italy
12/2018
Cancer- and chemotherapy-induced musculoskeletal complications
Pennsylvania State University
State College, PA
11/2019
Musculoskeletal complications of cancer and its treatments
12th Cachexia Conference
Berlin, Germany
12/2019
Mitochondria-targeted strategies ameliorate chemotherapy-induced cachexia
The New York Academy of Sciences – Confronting Cachexia
04/2021
Tumor- and host-derived factors drive musculoskeletal complication in cancer cachexia
Indiana University School of Medicine
08/2021
Mechanisms of chemotherapy-induced musculoskeletal complications
6th Cancer Cachexia Hybrid Conference
Virtual
08/2021
Musculoskeletal defects induced by cancer and its treatments
Université Catholique de Louvain
Virtual
10/2021
Musculoskeletal complications of cancer and its treatments
Inside Scientific & American Physiological Society, Webinar
Virtual
11/2021
Targeting RANKL for the treatment of muscle and bone defects in cachexia
XXXVI Annual Meeting of the Chilean Society of Physiological Sciences
Virtual
11/2021
Tumor- and host-derived factors drive musculoskeletal complication in cancer cachexia
Myology Institute Seminar Serie
University of Florida
Virtual
02/2022
